课题基金 / 基金详情

Genetic and brain mechanisms of naltrexone's treatment efficacy for alcoholism

Genetic and brain mechanisms of naltrexone's treatment efficacy for alcoholism
纳曲酮治疗酒精中毒疗效的遗传和脑机制
批准号:
8270569
负责人:
RAYMOND F ANTON
金额:
$51.24万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-15 至 2014-04-30

项目摘要

项目成果

RAYMOND F ANTON的其他基金

相似基金

相关文献

中文摘要
翻译
酒精依赖影响着1800万至2000万美国人,每年给我们的社会造成超过1850亿美元的损失。 这种疾病的治疗并不普遍,现有的治疗方法也不普遍。 有效阿片类药物拮抗剂纳洛酮,10多年前由FDA批准,是最好的药物之一。 有效的药物治疗酒精依赖,但没有广泛使用,不工作, 大家它缺乏广泛接受的原因包括它的低到中等程度的改善, 安慰剂及其作用机制的不完全知识。遗传药理学的最新进展 神经影像学为研究这些问题提供了新的工具。例如,在联合收割机研究中,我们 最近证实,μ阿片受体(OPRM 1)中相对常见的遗传变异(Asp 40) 可能与对纳洛酮的较高治疗反应有关。此外,使用高级功能 磁共振脑成像范例,我们的小组最近表明,纳洛酮可以钝化 酒精线索诱导的腹侧纹状体-中脑核和内侧前额叶皮层的激活, 不寻求治疗的酗酒者。我们还发现,类似的酒精线索诱导 内侧前额叶区的激活与治疗期间随后的大量饮酒有关。 酒精依赖者。本提案的目的是以前瞻性受控方式检查 OPRM 1受体的Asp 40变体是否能预测纳洛酮反应。此外,我们会 检查纳洛酮是否可以减少/抑制酒精线索诱导的腹侧纹状体激活, 内侧前额叶皮层,并探讨这种抑制是否可能与治疗反应有关。 最后,我们将评估Asp 40个体是否会有更多的纳洛酮抑制酒精提示- 诱导的大脑激活,如果这将介导药物与基因型之间的相互作用, 治疗为此,将筛选320名酒精依赖者,并将160名随机分为16周的 临床试验在OPRM 1基因分型后,80名至少有一个Asp 40等位基因拷贝的个体和80名 Asn 40同质的个体将随机分配至纳洛酮或安慰剂组,形成2 药物(纳洛酮或安慰剂)通过2个OPRM 1基因型(Asp 40 by Asn 40)设计。所有受试者将进行 在治疗随机化之前以及在治疗随机化的第7-14天之间再次进行酒精提示诱导的fMRI脑成像。 治疗,并将在16周内(以及第28周和第40周的随访期间)对饮酒和 其他显著的结果变量。主要结果变量将是重度饮酒天数百分比的差异, 临床总体结局。结果将有助于治疗提供者决定谁可能更好地应对 纳洛酮(以及延伸的其它未来的阿片样物质拮抗剂)和通过阐明何种机制(即, 减少酒精提示显着性)这种和其他类似的药物可能会工作。因此, 可以大大加强对酒精依赖者的治疗。
英文摘要
Alcohol dependence affects 18-20 million Americans and costs our society over $185 billion annually. Treatment for this disorder in not universally accessible and those treatments that exist are not universally effective. The opioid antagonist, naltrexone, approved by the FDA more than 10 years ago, is one of the most efficacious medication treatments for alcohol dependence, but is not widely used and does not work for everyone. Reasons for its lack of widespread acceptance include its low to moderate improvement over placebo and incomplete knowledge of its mechanism of action. Recent advances in pharmacogenetics and neuroimaging have provided new tools to investigate these issues. For instance, in the COMBINE Study we have recently confirmed that a relatively common genetic variant (Asp40) in a mu opioid receptor (OPRM1) may be associated with a higher treatment response to naltrexone. In addition, using advanced functional magnetic resonance brain imaging paradigms, our group has recently shown that naltrexone can blunt the alcohol cue-induced activation in the ventral striatum-nucleus accumbens and in medial prefrontal cortex, of actively-drinking non-treatment seeking alcoholics. We have also discovered that similar alcohol cue-induced activation of the medial prefrontal area is associated with subsequent heavy drinking during treatment of alcohol dependent individuals. The goal of this proposal is to examine in a prospective controlled fashion whether the Asp40 variant of the OPRM1 receptor will predict naltrexone response. In addition, we will examine whether naltrexone might reduce/dampen alcohol cue-induced activation of the ventral-striatum and medial prefrontal cortex and explore whether this dampening might be associated with treatment response. Finally, we will evaluate whether Asp40 individuals will have more naltrexone dampening of alcohol cue- induced brain activation and if this will mediate the medication by genotype interaction observed during treatment. To that end, 320 alcohol dependent individuals will be screened and 160 randomized into a 16-week clinical trial. After OPRM1 genotyping, 80 individuals with at least one copy of the Asp40 allele and 80 individuals who are homogenous for Asn40 will be randomized to naltrexone or placebo, forming a 2 medication (naltrexone or placebo) by 2 OPRM1 genotype (Asp40 by Asn40) design. All subjects will undergo alcohol cue-induced fMRI brain imaging prior to treatment randomization and again between days 7-14 of treatment and will be evaluated over 16 weeks (and during follow-up at weeks 28 and 40) for drinking and other salient outcome variables. Main outcome variables will be differences in percent heavy drinking days and clinical global outcome. Results will assist treatment providers in deciding who might better respond to naltrexone (and by extension other future opioid antagonists) and by elucidating by what mechanism (i.e., reduced alcohol cue salience) this and other similar medications might work. As such, improvement in the treatment of individuals with alcohol dependence could be greatly enhanced.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects
Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects
Gabapentin for Relapse Prevention: Alc. Withdrawal-Brain GABA/Glutamate Effects
Genetic and brain mechanisms of naltrexone's treatment efficacy for alcoholism
海外基金